A recent study found that the mortality rate of the high Foxp3 +/CD4+ TIL ratio group was 3.5 times higher than that of the low ratio group after observing the distribution of immune cells of 57 HCC patients in tumor tissue and peritumor tissue and the correlation of immune cells with clinical outcome. This evidence concerns the gene FOXP3 and neoplasm.